CAJ | 학술논문

目的：评估卡泊芬净治疗儿童血液病化疗或造血干细胞移植（HSCT）过程中真菌感染的疗效和安全性。方法2010年4月-2013年3月我科35例血液病患儿化疗或HSCT过程中出现真菌感染，予卡泊芬净治疗，第1天予单次负荷剂量70 mg/（m2·d）（实际剂量不超过70 mg/d），随后维持剂量50 mg/（m2·d）（实际剂量不超过70 mg/d），回顾性分析其疗效和安全性。结果卡泊芬净治疗35例儿童血液病化疗或HSCT过程真菌感染总有效率为71％（25/35），毒副作用发生率为3％（1/35）。其毒副作用表现为可逆性肝功能损害，停药后好转。结论卡泊芬净有效率高，安全性好，可以作为儿童血液病化疗或HSCT过程中真菌感染治疗的选择。
목적：평고잡박분정치료인동혈액병화료혹조혈간세포이식（HSCT）과정중진균감염적료효화안전성。방법2010년4월-2013년3월아과35례혈액병환인화료혹HSCT과정중출현진균감염，여잡박분정치료，제1천여단차부하제량70 mg/（m2·d）（실제제량불초과70 mg/d），수후유지제량50 mg/（m2·d）（실제제량불초과70 mg/d），회고성분석기료효화안전성。결과잡박분정치료35례인동혈액병화료혹HSCT과정진균감염총유효솔위71％（25/35），독부작용발생솔위3％（1/35）。기독부작용표현위가역성간공능손해，정약후호전。결론잡박분정유효솔고，안전성호，가이작위인동혈액병화료혹HSCT과정중진균감염치료적선택。
Objective To evaluate the efficacy and safety of caspofungin therapy in fungal infection of pediatric hematological patients accepting chemotherapy or hematopoietic stem cell transplantation.MethodsFrom April 2010 to March 2013,there were thirty-five pediatric hematological patients with fungal infection,they were treated with caspofungin in first dose of 70 mg/(m2 ·d ),and followed by maintenance dose of 50 mg/(m2 ·d ),of which the clinical efficacy and side effects were analyzed retrospectively.Results The overall clinical efficacy rate of caspofungin was 7 1% and the incidence of side effects was 3%. The side effect was hepatic dysfunction, which is reversible. Conclusions Caspofungin therapy provides high efficacy and safety in these thirty-five pediatric patients.It may be a good choice as a therapy in fungal infection for the pediatric hematological patients accepting chemotherapy or hematopoietic stem cell transplantation.